Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110377 | 0.78 | MAPT (0.39) | MAPTBRD4MEN1KMT2A | |
| SCHEMBL3410563 | 0.71 | NPY1R (0.48) | NPY1RNPC1KMT2A | |
| SCHEMBL3413644 | 0.71 | NPY1R (0.46) | NPY1R | |
| SCHEMBL3414719 | 0.70 | NPY1R (0.45) | NPY1R | |
| SCHEMBL3414720 | 0.69 | NPY1R (0.45) | NPY1RMAPTMEN1NPC1POLB | |
| SCHEMBL3408465 | 0.69 | NPY1R (0.44) | NPY1RNPC1 | |
| SCHEMBL3406614 | 0.69 | NPC1 (0.44) | NPY1RMAPTMEN1NPC1KMT2A | |
| SCHEMBL3413266 | 0.67 | TRPV1 (0.45) | NPY1RNPC1POLBKMT2A | |
| SCHEMBL19020205 | 0.67 | RAB9A (0.65) | MAPTMEN1NPC1POLBKMT2A | |
| SCHEMBL3402556 | 0.66 | POLB (0.38) | MAPTMEN1NPC1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350028-B2 | 2-aminoquinolines | HOFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2254666-A1 | 2-AMINOQUINOLINES AS 5-HT5A RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009112395-A1 | 2-AMINOQUINOLINES AS 5-HT5A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233927-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233927-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | NPY1R 89/4885MAPT 903/4885PARP1 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.